Paul Blanchfield
President at LANTHEUS HOLDINGS, INC.
Net worth: 7 M $ as of 2024-04-29
Paul Blanchfield active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LANTHEUS HOLDINGS, INC. | President | 2023-03-19 | - |
| Chief Operating Officer | 2022-06-14 | 2023-03-19 | |
| Corporate Officer/Principal | 2020-01-26 | 2022-06-14 |
Career history of Paul Blanchfield
Former positions of Paul Blanchfield
| Companies | Position | Start | End |
|---|---|---|---|
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | - | - |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - | - |
Training of Paul Blanchfield
| Stanford University | Graduate Degree |
| Duke University | Undergraduate Degree |
Statistics
International
| United States | 4 |
| Japan | 2 |
| United Kingdom | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 1 |
| President | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| LANTHEUS HOLDINGS, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Private companies | 1 |
|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Stock Market
- Insiders
- Paul Blanchfield
- Experience
